Annual CFO
-$73.34 M
-$104.12 M-338.20%
31 December 2023
Summary:
NovoCure Limited annual cash flow from operations is currently -$73.34 million, with the most recent change of -$104.12 million (-338.20%) on 31 December 2023. During the last 3 years, it has fallen by -$172.48 million (-173.97%). NVCR annual CFO is now -173.97% below its all-time high of $99.15 million, reached on 31 December 2020.NVCR Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$10.38 M
+$12.10 M+703.26%
30 September 2024
Summary:
NovoCure Limited quarterly cash flow from operations is currently $10.38 million, with the most recent change of +$12.10 million (+703.26%) on 30 September 2024. Over the past year, it has increased by +$29.69 million (+153.72%). NVCR quarterly CFO is now -80.60% below its all-time high of $53.48 million, reached on 31 December 2020.NVCR Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$37.48 M
+$29.69 M+44.20%
30 September 2024
Summary:
NovoCure Limited TTM cash flow from operations is currently -$37.48 million, with the most recent change of +$29.69 million (+44.20%) on 30 September 2024. Over the past year, it has increased by +$25.01 million (+40.02%). NVCR TTM CFO is now -129.19% below its all-time high of $128.40 million, reached on 30 June 2021.NVCR TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVCR Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -338.2% | +153.7% | +40.0% |
| 3 y3 years | -174.0% | -57.5% | -130.8% |
| 5 y5 years | -3832.2% | -30.4% | -202.8% |
NVCR Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -174.0% | at low | -57.5% | +132.9% | -130.8% | +57.5% |
| 5 y | 5 years | -174.0% | at low | -80.6% | +132.9% | -129.2% | +57.5% |
| alltime | all time | -174.0% | +31.8% | -80.6% | +131.0% | -129.2% | +68.8% |
NovoCure Limited Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.38 M(-703.3%) | -$37.48 M(-44.2%) |
| June 2024 | - | -$1.72 M(-94.6%) | -$67.17 M(-23.8%) |
| Mar 2024 | - | -$31.57 M(+116.9%) | -$88.18 M(+20.2%) |
| Dec 2023 | -$73.34 M(-338.2%) | -$14.56 M(-24.6%) | -$73.34 M(+17.4%) |
| Sept 2023 | - | -$19.31 M(-15.1%) | -$62.48 M(+201.1%) |
| June 2023 | - | -$22.74 M(+35.9%) | -$20.75 M(-216.9%) |
| Mar 2023 | - | -$16.73 M(+351.2%) | $17.75 M(-42.4%) |
| Dec 2022 | $30.79 M(-62.8%) | -$3.71 M(-116.5%) | $30.79 M(-37.0%) |
| Sept 2022 | - | $22.42 M(+42.2%) | $48.90 M(-3.9%) |
| June 2022 | - | $15.76 M(-527.5%) | $50.88 M(-17.0%) |
| Mar 2022 | - | -$3.69 M(-125.6%) | $61.29 M(-25.9%) |
| Dec 2021 | $82.76 M(-16.5%) | $14.40 M(-41.0%) | $82.76 M(-32.1%) |
| Sept 2021 | - | $24.40 M(-6.8%) | $121.83 M(-5.1%) |
| June 2021 | - | $26.17 M(+47.2%) | $128.40 M(+11.7%) |
| Mar 2021 | - | $17.78 M(-66.8%) | $114.97 M(+16.0%) |
| Dec 2020 | $99.15 M(+272.5%) | $53.48 M(+72.7%) | $99.15 M(+88.4%) |
| Sept 2020 | - | $30.97 M(+143.1%) | $52.63 M(+43.9%) |
| June 2020 | - | $12.74 M(+551.0%) | $36.57 M(+11.2%) |
| Mar 2020 | - | $1.96 M(-71.9%) | $32.89 M(+23.6%) |
| Dec 2019 | $26.62 M | $6.96 M(-53.3%) | $26.62 M(-27.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | $14.91 M(+64.4%) | $36.47 M(+34.1%) |
| June 2019 | - | $9.07 M(-310.1%) | $27.20 M(+155.6%) |
| Mar 2019 | - | -$4.32 M(-125.7%) | $10.64 M(-670.7%) |
| Dec 2018 | -$1.86 M(-94.4%) | $16.81 M(+198.2%) | -$1.86 M(-91.4%) |
| Sept 2018 | - | $5.64 M(-175.2%) | -$21.58 M(-12.5%) |
| June 2018 | - | -$7.49 M(-55.5%) | -$24.67 M(+7.0%) |
| Mar 2018 | - | -$16.82 M(+480.5%) | -$23.05 M(-30.4%) |
| Dec 2017 | -$33.13 M(-69.2%) | -$2.90 M(-213.7%) | -$33.13 M(-24.6%) |
| Sept 2017 | - | $2.55 M(-143.4%) | -$43.96 M(-45.1%) |
| June 2017 | - | -$5.88 M(-78.2%) | -$80.00 M(-22.7%) |
| Mar 2017 | - | -$26.91 M(+96.1%) | -$103.52 M(-3.8%) |
| Dec 2016 | -$107.59 M(+7.7%) | -$13.72 M(-59.0%) | -$107.59 M(-10.3%) |
| Sept 2016 | - | -$33.50 M(+14.0%) | -$119.99 M(+10.5%) |
| June 2016 | - | -$29.39 M(-5.1%) | -$108.60 M(+6.1%) |
| Mar 2016 | - | -$30.98 M(+18.6%) | -$102.39 M(+2.5%) |
| Dec 2015 | -$99.88 M(+34.5%) | -$26.12 M(+18.2%) | -$99.88 M(+35.4%) |
| Sept 2015 | - | -$22.11 M(-4.7%) | -$73.76 M(+42.8%) |
| June 2015 | - | -$23.19 M(-18.5%) | -$51.66 M(+81.5%) |
| Mar 2015 | - | -$28.47 M | -$28.47 M |
| Dec 2014 | -$74.24 M(+40.8%) | - | - |
| Dec 2013 | -$52.72 M | - | - |
FAQ
- What is NovoCure Limited annual cash flow from operations?
- What is the all time high annual CFO for NovoCure Limited?
- What is NovoCure Limited annual CFO year-on-year change?
- What is NovoCure Limited quarterly cash flow from operations?
- What is the all time high quarterly CFO for NovoCure Limited?
- What is NovoCure Limited quarterly CFO year-on-year change?
- What is NovoCure Limited TTM cash flow from operations?
- What is the all time high TTM CFO for NovoCure Limited?
- What is NovoCure Limited TTM CFO year-on-year change?
What is NovoCure Limited annual cash flow from operations?
The current annual CFO of NVCR is -$73.34 M
What is the all time high annual CFO for NovoCure Limited?
NovoCure Limited all-time high annual cash flow from operations is $99.15 M
What is NovoCure Limited annual CFO year-on-year change?
Over the past year, NVCR annual cash flow from operations has changed by -$104.12 M (-338.20%)
What is NovoCure Limited quarterly cash flow from operations?
The current quarterly CFO of NVCR is $10.38 M
What is the all time high quarterly CFO for NovoCure Limited?
NovoCure Limited all-time high quarterly cash flow from operations is $53.48 M
What is NovoCure Limited quarterly CFO year-on-year change?
Over the past year, NVCR quarterly cash flow from operations has changed by +$29.69 M (+153.72%)
What is NovoCure Limited TTM cash flow from operations?
The current TTM CFO of NVCR is -$37.48 M
What is the all time high TTM CFO for NovoCure Limited?
NovoCure Limited all-time high TTM cash flow from operations is $128.40 M
What is NovoCure Limited TTM CFO year-on-year change?
Over the past year, NVCR TTM cash flow from operations has changed by +$25.01 M (+40.02%)